The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy.

HLA-G is a non-classical MHC class I molecule with highly limited tissue distribution which has been attributed chiefly immune-regulatory functions. We previously have reported that HLA-G is expressed in inflamed muscle in vivo and by cultured myoblasts in vitro. Here, we used the in vitro models of human myoblasts or TE671 muscle rhabdomyosarcoma cells to characterize the functional role of HLA-G for muscle immune cell interactions. Gene transfer of the two major isoforms of HLA-G (transmembranous HLA-G1 and soluble HLA-G5) into TE671 rendered these cells resistant to alloreactive lysis by direct inhibition of natural killer (NK) cells, and CD4 and CD8 T cells. Further, HLA-G reduced alloproliferation, interfered with effective priming of antigen-specific cytotoxic T cells and reduced antigen-specific alloreactive lysis. HLA-G pre-induced on cultured myoblasts inhibited lysis by alloreactive peripheral blood mononuclear cells. This protection was reversed by a neutralizing HLA-G antibody. Interestingly, a few HLA-G-positive cells within a population of HLA-G-negative muscle target cells conveyed significant inhibitory effects on alloreactive lysis. Our results reveal further insights into the immunobiology of muscle and suggest that ectopic expression of HLA-G may promote the survival of transplanted myoblasts in the future treatment of hereditary muscle diseases. Further, HLA-G could represent a novel self-derived anti-inflammatory principle applicable in strategies against inflammatory aggression.

[1]  H. Rammensee,et al.  Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells , 1997, The Journal of experimental medicine.

[2]  R. Hohlfeld,et al.  Human myoblasts as antigen presenting cells , 1991, Journal of Neuroimmunology.

[3]  R. Hohlfeld,et al.  The immunobiology of muscle. , 1994, Immunology today.

[4]  P. Kavathas,et al.  Cell-cell adhesion mediated by CD8 and human histocompatibility leukocyte antigen G, a nonclassical major histocompatibility complex class 1 molecule on cytotrophoblasts , 1991, The Journal of experimental medicine.

[5]  H. Rammensee,et al.  Nonclassical HLA-G molecules are classical peptide presenters , 1996, Current Biology.

[6]  R. R. Rice,et al.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy. , 1995, The New England journal of medicine.

[7]  S. Ferrone,et al.  Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. , 2000, International immunology.

[8]  Margaret A. Johnson,et al.  Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G , 2000, Annals of neurology.

[9]  J. Dausset,et al.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Dalakas.  Polymyositis, dermatomyositis and inclusion-body myositis. , 1991, The New England journal of medicine.

[11]  S. Hiby,et al.  HLA‐G Expression by Tumors , 2001, American journal of reproductive immunology.

[12]  M. Shuman,et al.  Retraction: Stricker RB, Abrams DI, Corash L, Shuman MA. Target platelet antigen in homosexual men with immune thrombocytopenia. N Engl J Med 1985; 313:1375-80. , 1991 .

[13]  V. Guiard,et al.  © 1999 The Japanese Society for Immunology IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes , 2022 .

[14]  J. Szulc.  Muscle-mediated gene therapy. , 1999, Folia histochemica et cytobiologica.

[15]  J. Dausset,et al.  Human Leukocyte Antigen-G Expression After Heart Transplantation Is Associated With a Reduced Incidence of Rejection , 2002, Circulation.

[16]  S. Fisher,et al.  A class I antigen, HLA-G, expressed in human trophoblasts. , 1990, Science.

[17]  P. Le Bouteiller,et al.  Is antigen presentation the primary function of HLA-G? , 2001, Microbes and infection.

[18]  D. Pardoll,et al.  Exposing the immunology of naked DNA vaccines. , 1995, Immunity.

[19]  D. Geraghty,et al.  Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Sercarz,et al.  Genetic vaccination: The advantages of going naked , 1996, Nature Medicine.

[21]  J. Dausset,et al.  Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  O. Mandelboim,et al.  Protection from Natural Killer Cell-Mediated Lysis by HLA-G Expression on Target Cells , 1996, Science.

[23]  J. Dausset,et al.  HLA-G2, -G3, and -G4 Isoforms Expressed as Nonmature Cell Surface Glycoproteins Inhibit NK and Antigen-Specific CTL Cytolysis1 , 2001, The Journal of Immunology.

[24]  N. Rouas-Freiss,et al.  HLA-G and HLA-E: fundamental and Pathophysiological aspects. , 2000, Immunology today.

[25]  J. Dausset,et al.  HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. , 2001, International immunology.

[26]  M. Krönke,et al.  Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes , 1996, Nature Medicine.

[27]  J. Dichgans,et al.  Topoisomerase‐I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl‐2 expression and of CD95‐mediated apoptosis by camptothecin and β‐lapachone , 1997, International journal of cancer.

[28]  J. Dausset,et al.  Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. , 2000, Human immunology.

[29]  J. Dausset,et al.  The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Dausset,et al.  Implication of HLA-G molecule in heart-graft acceptance , 2000, The Lancet.

[31]  J. Dausset,et al.  A Specific Interferon (IFN)-stimulated Response Element of the Distal HLA-G Promoter Binds IFN-regulatory Factor 1 and Mediates Enhancement of This Nonclassical Class I Gene by IFN-β* , 2001, The Journal of Biological Chemistry.

[32]  M. Grounds,et al.  Immunobiology and the future of myoblast transfer therapy. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Dausset,et al.  Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Geraghty,et al.  A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. , 1994, Journal of immunology.

[35]  J. Dausset,et al.  HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. , 1999, International immunology.

[36]  N. Rouas-Freiss,et al.  HLA-G: a shield against inflammatory aggression. , 2001, Trends in immunology.

[37]  O. Mandelboim,et al.  Multiple receptors for HLA-G on human natural killer cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Hohlfeld,et al.  Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. , 1998, Journal of immunology.

[39]  M. Dalakas,et al.  Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. , 1999, The American journal of pathology.

[40]  A. Toubert,et al.  Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD81 , 2000, The Journal of Immunology.

[41]  H. Rammensee,et al.  Peptide presentation and NK inhibition by HLA-G. , 1999, Journal of reproductive immunology.

[42]  S. Fisher,et al.  Identification of a Thymic Epithelial Cell Subset Sharing Expression of the Class Ib HLA-G Molecule with Fetal Trophoblasts , 1997, The Journal of experimental medicine.

[43]  R. Hohlfeld,et al.  Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. , 1993, The American journal of pathology.

[44]  A. Vincent,et al.  Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNγ secretion and cytotoxicity , 1998, Journal of Neuroimmunology.

[45]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[46]  D. Geraghty,et al.  Cytokine regulation of HLA-G expression in human trophoblast cell lines. , 1995, Journal of reproductive immunology.

[47]  M. Weller,et al.  A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.

[48]  D. Geraghty,et al.  Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. , 1996, Journal of immunology.

[49]  R. Hohlfeld,et al.  Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. , 1990, The Journal of clinical investigation.